In Brief: Cambridge Biotech
This article was originally published in The Gray Sheet
Executive Summary
Cambridge Biotech: U.S. Bankruptcy Court upholds the company's license to HIV-2 tests from Pasteur Sanofi, which had been challenged by Institut Pasteur and Genetic Systems in a patent infringement suit filed in March. However, the court enjoined Cambridge Biotech from sale of its Western Blot HIV-1 test, ruling that it infringed an Institut Pasteur patent. Cambridge Biotech, which in July 1994 filed for bankruptcy under Chapter 11 of the U.S. Bankruptcy Code, says that the court's decisions will allow it to "move forward" with its reorganization...
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.